ChromaDex Co. (NASDAQ:CDXC – Get Free Report)’s stock price traded down 5.6% on Thursday . The stock traded as low as $7.47 and last traded at $7.39. 62,790 shares were traded during trading, a decline of 93% from the average session volume of 867,001 shares. The stock had previously closed at $7.83.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 6th. LADENBURG THALM/SH SH boosted their price target on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Finally, HC Wainwright boosted their price target on shares of ChromaDex from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, March 10th.
View Our Latest Analysis on CDXC
ChromaDex Price Performance
Institutional Investors Weigh In On ChromaDex
Large investors have recently modified their holdings of the business. D. E. Shaw & Co. Inc. boosted its position in shares of ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock valued at $5,365,000 after acquiring an additional 957,665 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of ChromaDex by 288.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock valued at $3,517,000 after acquiring an additional 492,148 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of ChromaDex by 189.0% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 506,186 shares of the company’s stock valued at $2,685,000 after acquiring an additional 331,014 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of ChromaDex during the 4th quarter valued at about $1,647,000. Finally, Renaissance Technologies LLC boosted its position in shares of ChromaDex by 68.0% during the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock valued at $3,781,000 after acquiring an additional 288,588 shares during the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Articles
- Five stocks we like better than ChromaDex
- Market Cap Calculator: How to Calculate Market Cap
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Investing in Construction Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- How to Capture the Benefits of Dividend Increases
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.